Design Therapeutics will present safety findings from its Phase 1 trial of DT-168, a potential first disease-modifying eye drop treatment for Fuchs endothelial corneal dystrophy, at Eyecelerator @ Park City 2025 on May 2.
Design Therapeutics has appointed Chris Storgard, M.D., as Chief Medical Officer, bringing over two decades of leadership in drug development with experience advancing multiple assets through global regulatory approvals.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.